Gatersleben: Europe’s plant breeders won the political argument over gene editing in June. They now face two years in which the regulation exists, applies to nothing, and depends on secondary legislation nobody has drafted.
The regulation on plants obtained by new genomic techniques cleared its final hurdles this summer. The Council adopted it on 21 April 2026, Parliament gave final approval on 17 June, publication in the Official Journal followed on 26 June and entry into force on 16 July. Application, however, waits until 17 July 2028. The two-year gap exists so the Commission can write the implementing and delegated acts that turn a framework into a working authorisation system.
The framework splits gene-edited plants into two categories. Category one covers plants judged equivalent to what conventional breeding could produce, and routes them through a simplified verification pathway rather than the full GMO regime. Category two keeps everything else inside the existing rules on genetically modified organisms, with the risk assessment, authorisation and traceability obligations that implies. The commercial value of the reform sits almost entirely in category one, and so does the drafting difficulty.
Deciding equivalence requires criteria precise enough to survive judicial review. How many edits, of what type, at which loci, before a plant stops resembling a conventionally bred variety? The regulation sets the principle. The implementing acts set the thresholds, and every breeder, seed company, organic certifier and importing partner has a direct interest in where those thresholds land. The European Food Safety Authority carries much of the technical burden of building the assessment methodology underneath them.
Member states carry their own two-year task. National competent authorities need verification procedures, seed catalogues need updating, and labelling rules for category one plants have to work at retail without confusing shoppers who have spent twenty-five years reading GMO labels. Organic producers, who remain outside the category one pathway entirely, need coexistence measures that protect their certification when a neighbouring field is planted with an edited variety.
Critics have not gone quiet after losing the vote. Environmental and organic groups argue the simplified pathway strips out traceability that farmers and consumers rely on, and that equivalence to conventional breeding is a legal fiction rather than a biological finding. Supporters answer that the previous regime treated a single base-pair edit and a transgenic insertion identically, blocked drought and disease resistance work that European labs had already done, and pushed the resulting varieties to markets outside the Union. Both positions will be relitigated through the implementing acts, which is where technical drafting usually absorbs political disagreement.
Trade adds pressure. Several major agricultural exporters already authorise gene-edited varieties under lighter regimes, and importers need to know by 2028 which of those products enter the Union under which pathway. Alignment questions with trading partners tend to surface late in the drafting of technical annexes.
Breeders working today therefore plan against criteria that do not yet exist. That is a normal condition in EU law and an uncomfortable one in a sector where a variety takes eight to ten years from cross to market. The Commission’s technical pages on new genomic techniques and the Council’s adoption statement set out the framework as agreed.
